相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2022)
Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece
Dimitra Petropoulou et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance
Jacqueline Findlay et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2022)
Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians
Luigi Principe et al.
PHARMACEUTICALS (2022)
Carbapenem-resistant Acinetobacter baumannii: A challenge in the intensive care unit
Yuan Jiang et al.
FRONTIERS IN MICROBIOLOGY (2022)
In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
In Vitro Activity of Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy
Bernardetta Segatore et al.
ANTIBIOTICS-BASEL (2022)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-ResistantAcinetobacter baumannii: A Prospective, Observational Study
Alessandro Russo et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Virulence Potential and Treatment Options of Multidrug-Resistant (MDR) Acinetobacter baumannii
Sunil Kumar et al.
MICROORGANISMS (2021)
In vitro activity of sulbactam/durlobactam against extensively drug-resistant Acinetobacter baumannii isolates belonging to South American major clones
Carolina S. Nodari et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
Adam B. Shapiro et al.
FRONTIERS IN MICROBIOLOGY (2021)
In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017
Sarah M. McLeod et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China
Qiwen Yang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
Harald Seifert et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii
Corneliu Ovidiu Vrancianu et al.
MICROORGANISMS (2020)
Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent
Melissa D. Barnes et al.
MBIO (2019)
Global Surveillance of the Activity of Sulbactam Combined With the Novel β-lactamase Inhibitor ETX2514 Against Clinical Isolates of Acinetobacter baumannii From 2014
Alita Miller et al.
Open Forum Infectious Diseases (2017)
Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii
William F. Penwell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii
Shu-Chen Kuo et al.
FRONTIERS IN MICROBIOLOGY (2015)
Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
Rujipas Sirijatuphat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Update on Acinetobacter Species: Mechanisms of Antimicrobial Resistance and Contemporary In Vitro Activity of Minocycline and Other Treatment Options
Mariana Castanheira et al.
CLINICAL INFECTIOUS DISEASES (2014)
Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis
E. V. Lemos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii
Lenka Krizova et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Trends in Antimicrobial Resistance of Acinetobacter baumannii Isolates from a Metropolitan Detroit Health System
Tara Reddy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)